Professor Michael Friedlander
Conjoint Professor

Professor Michael Friedlander

Medicine & Health
School of Clinical Medicine
Phone
9382 2606
  • Book Chapters | 2020
    Christie EL; Freimund AE; Fereday S; Alsop K; Hoang T; Pishas K; Au-Yeung G; Friedlander M; Bowtell DD, 2020, 'The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer', in Overcoming Ovarian Cancer Chemoresistance, Elsevier, pp. 43 - 53, http://dx.doi.org/10.1016/B978-0-12-819840-7.00013-3
  • Journal articles | 2023
    Meagher NS; Hamilton P; Milne K; Thornton S; Harris B; Weir A; Alsop J; Bisinoto C; Brenton JD; Brooks-Wilson A; Chiu DS; Cushing-Haugen KL; Fereday S; Garsed DW; Gayther SA; Gentry-Maharaj A; Gilks B; Jimenez-Linan M; Kennedy CJ; Le ND; Piskorz AM; Riggan MJ; Shah M; Singh N; Talhouk A; Widschwendter M; Bowtell DDL; Candido dos Reis FJ; Cook LS; Fortner RT; García MJ; Harris HR; Huntsman DG; Karnezis AN; Köbel M; Menon U; Pharoah PDP; Doherty JA; Anglesio MS; Pike MC; Pearce CL; Friedlander ML; DeFazio A; Nelson BH; Ramus SJ, 2023, 'Profiling the immune landscape in mucinous ovarian carcinoma', Gynecologic Oncology, vol. 168, pp. 23 - 31, http://dx.doi.org/10.1016/j.ygyno.2022.10.022
    Journal articles | 2022
    Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL, 2022, 'Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial', Gynecologic Oncology, vol. 164, pp. 278 - 287, http://dx.doi.org/10.1016/j.ygyno.2021.12.012
    Journal articles | 2022
    Cho D; Lord SJ; Simes J; Cooper W; Friedlander M; Bae S; Lee CK, 2022, 'Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework', Therapeutic Advances in Medical Oncology, vol. 14, http://dx.doi.org/10.1177/17588359221112822
    Journal articles | 2022
    DiSilvestro P; Banerjee S; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander ML; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Oza AM; Gonzalez Martin AJ; Aghajanian C; Bradley WH; Mathews C; McNamara J; Lowe E; Moore KN, 2022, '517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial', Annals of Oncology, vol. 33, pp. S779 - S779, http://dx.doi.org/10.1016/j.annonc.2022.07.645
    Journal articles | 2022
    Gersekowski K; Delahunty R; Alsop K; Goode EL; Cunningham JM; Winham SJ; Pharoah P; Song H; Jordan S; Fereday S; DeFazio A; Friedlander M; Obermair A; Webb PM, 2022, 'Germline BRCA variants, lifestyle and ovarian cancer survival', Gynecologic Oncology, vol. 165, pp. 437 - 445, http://dx.doi.org/10.1016/j.ygyno.2022.03.020
    Journal articles | 2022
    Konstantinopoulos PA; Gonzalez-Martin A; Cruz FM; Friedlander M; Glasspool R; Lorusso D; Marth C; Monk BJ; Kim J-W; Hinson P; Ajipa O; Pretre V; Han Y; Matulonis UA, 2022, 'EPIK-O/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)', FUTURE ONCOLOGY, http://dx.doi.org/10.2217/fon-2022-0666
    Journal articles | 2022
    Meagher NS; Gorringe KL; Wakefield MJ; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt K-A; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DD; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; Gourley C; Grube M; Harnett P; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim B-G; Kim J-W; Kim J-H; Klett K; Koziak J; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubinski J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park SY; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ, 2022, 'Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes.', Clin Cancer Res, http://dx.doi.org/10.1158/1078-0432.CCR-22-1206
    Journal articles | 2021
    Berek JS; Renz M; Kehoe S; Kumar L; Friedlander M, 2021, 'Cancer of the ovary, fallopian tube, and peritoneum: 2021 update', International Journal of Gynecology and Obstetrics, vol. 155, pp. 61 - 85, http://dx.doi.org/10.1002/ijgo.13878
    Journal articles | 2021
    Colombo N; Moore K; Scambia G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley WH; Kim JW; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P, 2021, 'Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial', Gynecologic Oncology, vol. 163, pp. 41 - 49, http://dx.doi.org/10.1016/j.ygyno.2021.07.016
    Journal articles | 2021
    Edmondson RJ; O'Connell RL; Banerjee S; Mileshkin L; Sykes P; Beale P; Fisher A; Bonaventura A; Millan D; Nottley S; Benson C; Hamilton A; Sjoquist K; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Friedlander M, 2021, 'Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)', Gynecologic Oncology, vol. 163, pp. 524 - 530, http://dx.doi.org/10.1016/j.ygyno.2021.09.010
    Journal articles | 2021
    Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; Chenevix-Trench G; Green A; Webb P; De Fazio A; Gertig D; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Bergh TV; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N, 2021, 'Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses', Modern Pathology, vol. 34, pp. 194 - 206, http://dx.doi.org/10.1038/s41379-020-0618-9
    Journal articles | 2021
    Kehm RD; MacInnis RJ; John EM; Liao Y; Kurian AW; Genkinger JM; Knight JA; Colonna S; Chung WK; Milne R; Zeinomar N; Dite GS; Southey MC; Giles GG; Mclachlan S-A; Whitaker KD; Friedlander ML; Weideman PC; Glendon G; Nesci S; Investigators K; Phillips K-A; Andrulis IL; Buys SS; Daly MB; Hopper JL; Terry MB, 2021, 'Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk', JNCI CANCER SPECTRUM, vol. 5, http://dx.doi.org/10.1093/jncics/pkab090
    Journal articles | 2021
    MacDonald C; Mazza D; Hickey M; Hunter M; Keogh LA; Jones SC; Saunders C; Nesci S; Milne RL; McLachlan SA; Hopper JL; Friedlander ML; Emery J; Phillips KA, 2021, 'Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians', JNCI Cancer Spectrum, vol. 5, http://dx.doi.org/10.1093/jncics/pkaa110
    Journal articles | 2021
    Quinn MCJ; McCue K; Shi W; Johnatty SE; Beesley J; Civitarese A; O'Mara TA; Glubb DM; Tyrer JP; Armasu SM; Ong JS; Gharahkhani P; Lu Y; Gao B; Patch AM; Fasching PA; Beckmann MW; Lambrechts D; Vergote I; Velez Edwards DR; Beeghly-Fadiel A; Benitez J; Garcia MJ; Goodman MT; Dörk T; Dürst M; Modugno F; Moysich K; Du Bois A; Pfisterer J; Bauman K; Karlan BY; Lester J; Cunningham JM; Larson MC; McCauley BM; Kjaer SK; Jensen A; Hogdall CK; Hogdall E; Schildkraut JM; Riggan MJ; Berchuck A; Cramer DW; Terry KL; Bjorge L; Webb PM; Friedlander M; Pejovic T; Moffitt M; Glasspool R; May T; Ene GEV; Huntsman DG; Woo M; Carney ME; Hinsley S; Heitz F; Fereday S; Kennedy CJ; Edwards SL; Winham SJ; DeFazio A; Pharoah PDP; Goode EL; MacGregor S; Chenevix-Trench G, 2021, 'Identification of a locus near ULK1 associated with progression-free survival in ovarian cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 30, pp. 1669 - 1680, http://dx.doi.org/10.1158/1055-9965.EPI-20-1817
    Journal articles | 2021
    Trinh T; Park SB; Murray J; Pickering H; Lin CSY; Martin A; Friedlander M; Kiernan MC; Goldstein D; Krishnan AV, 2021, 'Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial', Supportive Care in Cancer, vol. 29, pp. 1103 - 1110, http://dx.doi.org/10.1007/s00520-020-05591-x
    Journal articles | 2020
    Heinzelmann-Schwarz V; Kind AB; Vetter M; Russell K; Omar S; Schoetzau A; Hoeck K; Fink D; Friedlander ML; Hacker NF, 2020, 'Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?', Journal of Cancer Research and Clinical Oncology, vol. 146, pp. 695 - 704, http://dx.doi.org/10.1007/s00432-019-03091-y
    Journal articles | 2020
    Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK, 2020, 'Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis', JAMA network open, vol. 3, pp. e2011809, http://dx.doi.org/10.1001/jamanetworkopen.2020.11809
    Journal articles | 2020
    Millstein J; Budden T; Goode EL; Anglesio MS; Talhouk A; Intermaggio MP; Leong HS; Chen S; Elatre W; Gilks B; Nazeran T; Volchek M; Bentley RC; Wang C; Chiu DS; Kommoss S; Leung SCY; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; George J; Bowtell DD; Chenevix-Trench G; Green A; Webb P; deFazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier,a A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D, 2020, 'Prognostic gene expression signature for high-grade serous ovarian cancer', Annals of Oncology, vol. 31, pp. 1240 - 1250, http://dx.doi.org/10.1016/j.annonc.2020.05.019
    Journal articles | 2019
    Mileshkin L; Edmondson R; O'Connell RL; Sjoquist KM; Andrews J; Jyothirmayi R; Beale P; Bonaventura T; Goh J; Hall M; Clamp A; Green J; Lord R; Amant F; Alexander L; Carty K; Paul J; Scurry J; Millan D; Nottley S; Friedlander M, 2019, 'Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903', Gynecologic Oncology, vol. 154, pp. 29 - 37, http://dx.doi.org/10.1016/j.ygyno.2019.05.007
    Journal articles | 2019
    Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA, 2019, 'Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))', Gynecologic Oncology, vol. 152, pp. 220, http://dx.doi.org/10.1016/j.ygyno.2018.10.022
    Journal articles | 2019
    Rose PG; Java JJ; Salani R; Geller MA; Secord AA; Tewari KS; Bender DP; Mutch DG; Friedlander ML; Van Le L; Method MW; Hamilton CA; Lee RB; Wenham RM; Guntupalli SR; Markman M; Muggia FM; Armstrong DK; Bookman MA; Burger RA; Copeland LJ, 2019, 'Nomogram for Predicting Individual Survival after Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma', Obstetrics and Gynecology, vol. 133, pp. 245 - 254, http://dx.doi.org/10.1097/AOG.0000000000003086
    Journal articles | 2019
    Zeinomar N; Phillips KA; Daly MB; Milne RL; Dite GS; MacInnis RJ; Liao Y; Kehm RD; Knight JA; Southey MC; Chung WK; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; Buys SS; John EM; Hopper JL; Terry MB, 2019, 'Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort', International Journal of Cancer, vol. 145, pp. 370 - 379, http://dx.doi.org/10.1002/ijc.32112
    Journal articles | 2018
    Beesley VL; Smith DD; Nagle CM; Friedlander M; Grant P; DeFazio A; Webb PM, 2018, 'Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer', Supportive Care in Cancer, vol. 26, pp. 4133 - 4142, http://dx.doi.org/10.1007/s00520-018-4284-0
    Journal articles | 2018
    Block MS; Vierkant RA; Rambau PF; Winham SJ; Wagner P; Traficante N; Toloczko A; Tiezzi DG; Taran FA; Sinn P; Sieh W; Sharma R; Rothstein JH; Ramón y Cajal T; Paz-Ares L; Oszurek O; Orsulic S; Ness RB; Nelson G; Modugno F; Menkiszak J; McGuire V; McCauley BM; Mack M; Lubinski J; Longacre TA; Li Z; Lester J; Kennedy CJ; Kalli KR; Jung AY; Johnatty SE; Jimenez-Linan M; Jensen A; Intermaggio MP; Hung J; Herpel E; Hernandez BY; Hartkopf AD; Harnett PR; Ghatage P; García-Bueno JM; Gao B; Fereday S; Eilber U; Edwards RP; de Sousa CB; de Andrade JM; Chudecka-Glaz A; Chenevix-Trench G; Cazorla A; Brucker SY; Bowtell DD; Green A; Webb P; de Fazio A; Gertig D; Moore S; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R, 2018, 'MyD88 and TLR4 Expression in Epithelial Ovarian Cancer', Mayo Clinic Proceedings, vol. 93, pp. 307 - 320, http://dx.doi.org/10.1016/j.mayocp.2017.10.023
    Journal articles | 2018
    Deva S; Lee J-S; Lin C-C; Yen C-J; Millward M; Chao Y; Keam B; Jameson M; Hou M-M; Kang Y-K; Markman B; Lu C-H; Rau K-M; Lee K-H; Horvath L; Friedlander M; Hill A; Wu J; Hou J; Desai J, 2018, 'A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors', Annals of Oncology, vol. 29, pp. x24 - x25, http://dx.doi.org/10.1093/annonc/mdy487.042
    Journal articles | 2018
    Friedlander M; Gebski V; Gibbs E; Davies L; Bloomfield R; Hilpert F; Wenzel LB; Eek D; Rodrigues M; Clamp A; Penson RT; Provencher D; Korach J; Huzarski T; Vidal L; Salutari V; Scott C; Nicoletto MO; Tamura K; Espinoza D; Joly F; Pujade-Lauraine E, 2018, 'Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial', The Lancet Oncology, vol. 19, pp. 1126 - 1134, http://dx.doi.org/10.1016/S1470-2045(18)30343-7
    Journal articles | 2018
    Friedlander M; Rau J; Lee CK; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Hilpert F; King MT; Debruyne P; Bologna A; Malander S; Monk BJ; Petru E; Calvert P; Herzog TJ; Barrett C; du Bois A, 2018, 'Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy', Annals of Oncology, vol. 29, pp. 737 - 743, http://dx.doi.org/10.1093/annonc/mdx796
    Journal articles | 2018
    Friedlander M; Shannon C; Goh J; Scott C; Mileshkin L, 2018, 'Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib', Asia-Pacific Journal of Clinical Oncology, vol. 14, pp. 459 - 464, http://dx.doi.org/10.1111/ajco.13104
    Journal articles | 2018
    Han HS; Diéras V; Robson M; Palácová M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Garber JE; Shparyk Y; Chmielowska E; Jakobsen EH; Kaklamani V; Gradishar W; Ratajczak CK; Nickner C; Qin Q; Qian J; Shepherd SP; Isakoff SJ; Puhalla S, 2018, 'Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: Randomized phase II study', Annals of Oncology, vol. 29, pp. 154 - 161, http://dx.doi.org/10.1093/annonc/mdx505
    Journal articles | 2018
    Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA, 2018, 'Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study', Gynecologic Oncology, vol. 151, pp. 18 - 23, http://dx.doi.org/10.1016/j.ygyno.2018.07.021
    Journal articles | 2018
    Oskay-Özcelik G; Alavi S; Richter R; Keller M; Chekerov R; Cecere SC; Cormio G; Joly F; Kurtz JE; du Bois A; Maciejewski M; Jedryka M; Vergote I; Van Nieuwenhuysen E; Casado A; Mendiola C; Achimas-Cadariu P; Vlad C; Reimer D; Zeimet AG; Friedlander M; Sehouli J, 2018, 'Expression III: Patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries', Annals of Oncology, vol. 29, pp. 910 - 916, http://dx.doi.org/10.1093/annonc/mdy037
    Journal articles | 2017
    Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA; Buck M; Dean A; Friedlander ML; Harnett P; Kichenadasse G; Denys H; Dirix L; Vergote I; Elit L; Ghatage P; Plante M; Provencher D; Welch S; Gladieff L; Joly F; Lortholary A; Lotz J; Medioni J; Tredan O; You B; El-Balat A; Hänle C; Krabisch P; Neunhöffer T; Pölcher M; Wimberger P; Amit A; Kovel S; Leviov M; Safra T; Shapira-Frommer R; Stemmer S; Bologna A; Pignata S; Sabbatini RF; Tamberi S; Zamagni C; O'Donnell A; Herraez AC; Guerra EM; Palacio I; Romero I; Sanchez A; Banerjee SN; Drew Y; Gabra HG; Jackson D; Parkinson C; Powell M; Birrer MJ; Buss MK; Chambers SK; Chen LM; Ma L; Morgan MA; Morris RT; Mutch DG; Slomovitz BM; Vanderkwaak T; Vulfovich M, 2017, 'Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet, vol. 390, pp. 1949 - 1961, http://dx.doi.org/10.1016/S0140-6736(17)32440-6
    Journal articles | 2017
    Kondrashova O; Nguyen M; Shield-Artin K; Tinker AV; Teng NNH; Harrell MI; Kuiper MJ; Ho GY; Barker H; Jasin M; Prakash R; Kass EM; Sullivan MR; Brunette GJ; Bernstein KA; Coleman RL; Floquet A; Friedlander M; Kichenadasse G; O’Malley DM; Oza A; Sun J; Robillard L; Maloney L; Bowtell D; Giordano H; Wakefield MJ; Kaufmann SH; Simmons AD; Harding TC; Raponi M; McNeish IA; Swisher EM; Lin KK; Scott CL, 2017, 'Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma', Cancer Discovery, vol. 7, pp. 984 - 998, http://dx.doi.org/10.1158/2159-8290.CD-17-0419
    Journal articles | 2017
    Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips K-A; Mooij TM; Roos-Blom M-J; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC, 2017, 'Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 317, pp. 2402 - 2416, http://dx.doi.org/10.1001/jama.2017.7112
    Journal articles | 2017
    Mai PL; Piedmonte M; Han PK; Moser RP; Walker JL; Rodriguez G; Boggess J; Rutherford TJ; Zivanovic O; Cohn DE; Thigpen JT; Wenham RM; Friedlander ML; Hamilton CA; Bakkum-Gamez J; Olawaiye AB; Hensley ML; Greene MH; Huang HQ; Wenzel L, 2017, 'Factors Associated with Deciding between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study', Obstetrical and Gynecological Survey, vol. 72, pp. 336 - 337, http://dx.doi.org/10.1097/OGX.0000000000000451
    Journal articles | 2017
    Meniawy T; Richardson G; Townsend A; Desai J; Gan H; Friedlander M; Horvath L; Jameson MB; Sandhu S; Wu Z; Qin Z; Kang K; Markman B, 2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', Annals of Oncology, vol. 28, pp. v130 - v130, http://dx.doi.org/10.1093/annonc/mdx367.023
    Journal articles | 2017
    Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA, 2017, 'The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: A systematic review', Human Reproduction, vol. 32, pp. 1033 - 1045, http://dx.doi.org/10.1093/humrep/dex027
    Journal articles | 2017
    Roncolato FT; Joly F; O’Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M, 2017, 'Reducing uncertainty: Predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer—The GCIG symptombenefit study', Oncologist, vol. 22, pp. 1117 - 1124, http://dx.doi.org/10.1634/theoncologist.2017-0047
    Journal articles | 2017
    Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD, 2017, 'What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study', Cancer, vol. 123, pp. 985 - 993, http://dx.doi.org/10.1002/cncr.30414
    Journal articles | 2017
    Sandler CX; Goldstein D; Horsfield S; Bennett BK; Friedlander M; Bastick PA; Lewis CR; segelov E; Boyle FM; Chin MT; webber K; Barry BK; Lloyd AR, 2017, 'Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue.', Journal of Pain and Symptom Management, vol. 54, pp. 74 - 84, http://dx.doi.org/10.1016/j.jpainsymman.2017.03.015
    Journal articles | 2015
    Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM, 2015, 'Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation', Journal of Clinical Oncology, vol. 33, pp. 244 - 250, http://dx.doi.org/10.1200/JCO.2014.56.2728
    Journal articles | 2015
    Kondrashova O; Love CJ; Lunke S; Hsu AL; Bowtell D; Chenevix-Trench G; Green A; Webb P; DeFazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Houghton R; Russell P; Links M; Grygiel J; Hill J; Brand A; Byth K; Jaworski R; Harnett P; Sharma R; Wain G; Ward B; Papadimos D; Crandon A, 2015, 'High-throughput amplicon-based copy number detection of 11 genes in formalin-fixed paraffin-embedded ovarian tumour samples by MLPA-seq', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0143006
    Journal articles | 2015
    Patch AM; Christie EL; Etemadmoghadam D; Garsed DW; George J; Fereday S; Nones K; Cowin P; Alsop K; Bailey PJ; Kassahn KS; Newell F; Quinn MCJ; Kazakoff S; Quek K; Wilhelm-Benartzi C; Curry E; Leong HS; Hamilton A; Mileshkin L; Au-Yeung G; Kennedy C; Hung J; Chiew YE; Harnett P; Friedlander M; Pyman J; Cordner S; O'Brien P; Leditschke J; Young G; Strachan K; Waring P; Azar W; Mitchell C; Traficante N; Hendley J; Thorne H; Shackleton M; Miller DK; Arnau GM; Tothill RW; Holloway TP; Semple T; Harliwong I; Nourse C; Nourbakhsh E; Manning S; Idrisoglu S; Bruxner TJC; Christ AN; Poudel B; Holmes O; Anderson M; Leonard C; Lonie A; Hall N; Wood S; Taylor DF; Xu Q; Lynn Fink J; Waddell N; Drapkin R; Stronach E; Gabra H; Brown R; Jewell A; Nagaraj SH; Markham E; Wilson PJ; Ellul J; McNally O; Doyle MA; Vedururu R; Stewart C; Lengyel E; Pearson JV; Waddell N; Defazio A; Grimmond SM; Bowtell DDL, 2015, 'Whole-genome characterization of chemoresistant ovarian cancer', Nature, vol. 521, pp. 489 - 494, http://dx.doi.org/10.1038/nature14410
    Journal articles | 2015
    Peterlongo P; Chang-Claude J; Moysich KB; Rudolph A; Schmutzler RK; Simard J; Soucy P; Eeles RA; Easton DF; Hamann U; Wilkening S; Chen B; Rookus MA; Schmidt MK; Van Der Baan FH; Spurdle AB; Walker LC; Lose F; Maia AT; Montagna M; Matricardi L; Lubinski J; Jakubowska A; Garcia EBG; Olopade OI; Nussbaum RL; Nathanson KL; Domchek SM; Rebbeck TR; Arun BK; Karlan BY; Orsulic S; Lester J; Chung WK; Miron A; Southey MC; Goldgar DE; Buys SS; Janavicius R; Dorfling CM; Van Rensburg EJ; Ding YC; Neuhausen SL; Hansen TVO; Gerdes AM; Ejlertsen B; Jønson L; Osorio A; Martínez-Bouzas C; Benitez J; Conway EE; Blazer KR; Weitzel JN; Manoukian S; Peissel B; Zaffaroni D; Scuvera G; Barile M; Ficarazzi F; Mariette F; Fortuzzi S; Viel A; Giannini G; Papi L; Martayan A; Tibiletti MG; Radice P; Vratimos A; Fostira F; Garber JE; Donaldson A; Brewer C; Foo C; Evans DGR; Frost D; Eccles D; Brady A; Cook J; Tischkowitz M; Adlard J; Barwell J; Walker L; Izatt L; Side LE; Kennedy MJ; Rogers MT; Porteous ME; Morrison PJ; Platte R; Davidson R; Hodgson SV; Ellis S; Cole T; Godwin AK; Claes K; Van Maerken T; Meindl A; Gehrig A; Sutter C; Engel C, 2015, 'Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers', Cancer Epidemiology Biomarkers and Prevention, vol. 24, pp. 308 - 316, http://dx.doi.org/10.1158/1055-9965.EPI-14-0532
    Journal articles | 2015
    Scurry J; Hacker NF; Barlow E; Friedlander M; Jackson M, 2015, 'Is quantification of lymphovascular space invasion useful in stage 1B2 cervical carcinomas?', Journal of Obstetrics and Gynaecology, vol. 35, pp. 377 - 381, http://dx.doi.org/10.3109/01443615.2014.958448
    Journal articles | 2015
    Wilson MK; Collyar D; Chingos DT; Friedlander M; Ho TW; Karakasis K; Kaye S; Parmar MKB; Sydes MR; Tannock IF; Oza AM, 2015, 'Outcomes and endpoints in cancer trials: Bridging the divide', The Lancet Oncology, vol. 16, pp. e43 - e52, http://dx.doi.org/10.1016/S1470-2045(14)70380-8
    Journal articles | 2014
    Amant F; Floquet A; Friedlander M; Kristensen G; Mahner S; Nam EJ; Powell MA; Ray-Coquard I; Siddiqui N; Sykes P; Westermann AM; Seddon B, 2014, 'Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma', International Journal of Gynecological Cancer, vol. 24, pp. S67 - S72, http://dx.doi.org/10.1097/IGC.0000000000000205
    Journal articles | 2014
    Bock VL; Friedlander M; Waring D; Kossard S; Wood GK, 2014, 'Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: A case of localised urticarial vasculitis following anastrozole therapy and a review of the literature', Australasian Journal of Dermatology, vol. 55, pp. 282 - 285, http://dx.doi.org/10.1111/ajd.12110
    Journal articles | 2014
    Davis A; Tinker AV; Friedlander M, 2014, '"platinum resistant" ovarian cancer: What is it, who to treat and how to measure benefit?', Gynecologic Oncology, vol. 133, pp. 624 - 631, http://dx.doi.org/10.1016/j.ygyno.2014.02.038
    Journal articles | 2014
    Friedlander ML; Covens A; Glasspool RM; Hilpert F; Kristensen G; Kwon S; Selle F; Small W; Witteveen E; Russell P, 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract', International Journal of Gynecological Cancer, vol. 24, pp. S78 - S82, http://dx.doi.org/10.1097/IGC.0000000000000239
    Journal articles | 2014
    Gao B; Russell A; Beesley J; Chen XQ; Healey S; Henderson M; Wong M; Emmanuel C; Galletta L; Johnatty SE; Bowtell D; Haber M; Norris M; Harnett P; Chenevix-Trench G; Balleine RL; Defazio A; Gertig D; Green A; Webb P; Hung J; Moore S; Traficante N; Fereday S; Harrap K; Sadkowsky T; Pandeya N; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Links M; Grygiel J; Hill J; Brand A; Byth K; Jaworski R; Sharma R; Achen A; Wain G; Ward B; Papadimos D; Crandon A; Cummings M; Horwood K; Obermair A; Perrin L; Wyld D; Nicklin J; Davy M; Oehler MK; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Brown B; Rome R; Allen D; Grant P; Hyde S; Laurie R; Robbie M; Healy D, 2014, 'Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer', Scientific Reports, vol. 4, http://dx.doi.org/10.1038/srep04669
    Journal articles | 2014
    Hasegawa K; Nagao S; Yasuda M; Millan D; Viswanathan AN; Glasspool RM; Devouassoux-Shisheboran M; Covens A; Lorusso D; Kurzeder C; Kim JW; Gladieff L; Bryce J; Friedlander M; Fujiwara K, 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix', International Journal of Gynecological Cancer, vol. 24, pp. S90 - S95, http://dx.doi.org/10.1097/IGC.0000000000000297
    Journal articles | 2014
    Park SB; Kwok JB; Loy CT; Friedlander ML; Lin CSY; Krishnan AV; Lewis CR; Kiernan MC, 2014, 'Paclitaxel-induced neuropathy: Potential association of MAPT and GSK3B genotypes', BMC Cancer, vol. 14, http://dx.doi.org/10.1186/1471-2407-14-993
    Journal articles | 2014
    Reed NS; Gomez-Garcia E; Gallardo-Rincon D; Barrette B; Baumann K; Friedlander M; Kichenadasse G; Kim JW; Lorusso D; Mirza MR; Ray-Coquard I, 2014, 'Gynecologic cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary', International Journal of Gynecological Cancer, vol. 24, pp. S35 - S41, http://dx.doi.org/10.1097/IGC.0000000000000265
    Journal articles | 2014
    Reed NS; Pautier P; Åvall-Lundqvist E; Choi CH; Du Bois A; Friedlander M; Fyles A; Kichenadasse G; Provencher DM; Ray-Coquard I, 2014, 'Gynecologic cancer interGroup (GCIG) consensus review for ovarian small cell cancers', International Journal of Gynecological Cancer, vol. 24, pp. S30 - S34, http://dx.doi.org/10.1097/IGC.0000000000000293
    Journal articles | 2013
    Friedlander ML; King MT, 2013, 'Patient-reported outcomes in ovarian cancer clinical trials', Annals of Oncology, vol. 24, http://dx.doi.org/10.1093/annonc/mdt474
    Journal articles | 2013
    Olsen CM; Nagle CM; Whiteman DC; Ness R; Pearce CL; Pike MC; Rossing MA; Terry KL; Wu AH; Group S; Risch HA; Yu H; Doherty JA; Chang-Claude J; Hein R; Nickels S; Wang-Gohrke S; Goodman MT; Carney ME; Matsuno RK; Lurie G; Moysich K; Kjaer SK; Jensen A; Hogdall E; Goode EL; Fridley BL; Vierkant RA; Larson MC; Schildkraut J; Hoyo C; Moorman P; Weber RP; Cramer DW; Vitonis AF; Bandera EV; Olson SH; Rodriguez-Rodriguez L; King M; Brinton LA; Yang H; Garcia-Closas M; Lissowska J; Anton-Culver H; Ziogas A; Gayther SA; Ramus SJ; Menon U; Gentry-Maharaj A; Webb PM, 2013, 'Obesity and risk of ovarian cancer subtypes: Evidence from the Ovarian Cancer Association Consortium', Endocrine-Related Cancer, vol. 20, pp. 251 - 262, http://dx.doi.org/10.1530/ERC-12-0395
    Journal articles | 2013
    Park SB; Goldstein D; Krishnan AV; Lin CSY; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC, 2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, vol. 63, pp. 419 - 437, http://dx.doi.org/10.3322/caac.21204
    Journal articles | 2013
    Permuth-Wey J; Lawrenson K; Shen HC; Velkova A; Tyrer JP; Chen Z; Lin HY; Ann Chen Y; Tsai YY; Qu X; Ramus SJ; Karevan R; Lee J; Lee N; Larson MC; Aben KK; Anton-Culver H; Antonenkova N; Antoniou AC; Armasu SM; Bacot F; Baglietto L; Bandera EV; Barnholtz-Sloan J; Beckmann MW; Birrer MJ; Bloom G; Bogdanova N; Brinton LA; Brooks-Wilson A; Brown R; Butzow R; Cai Q; Campbell I; Chang-Claude J; Chanock S; Chenevix-Trench G; Cheng JQ; Cicek MS; Coetzee GA; Cook LS; Couch FJ; Cramer DW; Cunningham JM; Dansonka-Mieszkowska A; Despierre E; Doherty JA; Dörk T; Du Bois A; Dürst M; Easton DF; Eccles D; Edwards R; Ekici AB; Fasching PA; Fenstermacher DA; Flanagan JM; Garcia-Closas M; Gentry-Maharaj A; Giles GG; Glasspool RM; Gonzalez-Bosquet J; Goodman MT; Gore M; Górski B; Gronwald J; Hall P; Halle MK; Harter P; Heitz F; Hillemanns P; Hoatlin M; Høgdall CK; Høgdall E; Hosono S; Jakubowska A; Jensen A; Jim H; Kalli KR; Karlan BY; Kaye SB; Kelemen LE; Kiemeney LA; Kikkawa F; Konecny GE; Krakstad C; Krüger Kjaer S; Kupryjanczyk J; Lambrechts D; Lambrechts S; Lancaster JM; Le ND; Leminen A; Levine DA; Liang D; Kiong Lim B; Lin J; Lissowska J; Lu KH; Lubiński J, 2013, 'Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31', Nature Communications, vol. 4, http://dx.doi.org/10.1038/ncomms2613
    Journal articles | 2013
    Shen H; Fridley BL; Song H; Lawrenson K; Cunningham JM; Ramus SJ; Cicek MS; Tyrer J; Stram D; Larson MC; Köbel M; Ziogas A; Zheng W; Yang HP; Wu AH; Wozniak EL; Ling Woo Y; Winterhoff B; Wik E; Whittemore AS; Wentzensen N; Palmieri Weber R; Vitonis AF; Vincent D; Vierkant RA; Vergote I; Van Den Berg D; Van Altena AM; Tworoger SS; Thompson PJ; Tessier DC; Terry KL; Teo SH; Templeman C; Stram DO; Southey MC; Sieh W; Siddiqui N; Shvetsov YB; Shu XO; Shridhar V; Wang-Gohrke S; Severi G; Schwaab I; Salvesen HB; Rzepecka IK; Runnebaum IB; Anne Rossing M; Rodriguez-Rodriguez L; Risch HA; Renner SP; Poole EM; Pike MC; Phelan CM; Pelttari LM; Pejovic T; Paul J; Orlow I; Zawiah Omar S; Olson SH; Odunsi K; Nickels S; Nevanlinna H; Ness RB; Narod SA; Nakanishi T; Moysich KB; Monteiro ANA; Moes-Sosnowska J; Modugno F; Menon U; McLaughlin JR; McGuire V; Matsuo K; Mat Adenan NA; Massuger LFAG; Lurie G; Lundvall L; Lubiński J; Lissowska J; Levine DA; Leminen A; Lee AW; Le ND; Lambrechts S; Lambrechts D; Kupryjanczyk J; Krakstad C; Konecny GE; Krüger Kjaer S; Kiemeney LA; Kelemen LE; Keeney GL; Karlan BY; Karevan R; Kalli KR; Kajiyama H; Ji BT; Jensen A; Jakubowska A, 2013, 'Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer', Nature Communications, vol. 4, http://dx.doi.org/10.1038/ncomms2629
    Journal articles | 2013
    Sjoquist KM; Friedlander ML; O'Connell RL; Voysey M; King MT; Stockler MR; Oza AM; Gillies K; Martyn JK; Butow PN, 2013, 'Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: The gynecologic cancer intergroup symptom benefit study', Oncologist, vol. 18, pp. 1221 - 1228, http://dx.doi.org/10.1634/theoncologist.2013-0175
    Journal articles | 2013
    Sommeijer DW; Sjoquist KM; Friedlander M, 2013, 'Hormonal treatment in recurrent and metastatic gynaecological cancers: A review of the current literature', Current Oncology Reports, vol. 15, pp. 541 - 548, http://dx.doi.org/10.1007/s11912-013-0343-3
    Journal articles | 2013
    Webber K; Girgis A; Bennett BK; Bonaventura A; Boyle FM; Koh E-S; Friedlander M; Segelov E; Goldstein D, 2013, 'The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).', Journal of Clinical Oncology, vol. 31, pp. 9602 - 9602, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9602
    Journal articles | 2011
    Park SB; Lin CS-Y; Krishnan AV; Friedlander M; Lewis C; Kiernan MC, 2011, 'Early Progressive and Sustained Dysfunction of Sensory Axons Underlies Paclitaxel-induced Neuropathy', Muscle and Nerve, vol. 43, pp. 367 - 374, http://dx.doi.org/10.1002/mus.21874
    Journal articles | 2011
    Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Long-term neuropathy after Oxaliplatin treatment: Challenging the dictum of reversibility', Oncologist, vol. 16, pp. 708 - 716, http://dx.doi.org/10.1634/theoncologist.2010-0248
    Journal articles | 2011
    Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy', Experimental Neurology, vol. 227, pp. 120 - 127, http://dx.doi.org/10.1016/j.expneurol.2010.10.002
    Journal articles | 2011
    Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Lang I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thuerlimann B, 2011, 'Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up', LANCET ONCOLOGY, vol. 12, pp. 1101 - 1108, http://dx.doi.org/10.1016/S1470-2045(11)70270-4
    Journal articles | 2011
    Rustin G; Vergote I; Eisenhauer E; Pujade-lauraine E; Quinn M; Thigpen T; Du bois A; Kristensen G; Jakobsen A; Sagae S; Greven K; Parmar M; Friedlander M; Cervantes A; Vermorken J, 2011, 'Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 Agreed by the gynecological cancer intergroup (GCIG)', International Journal of Gynecological Cancer, vol. 21, pp. 419 - 423, http://dx.doi.org/10.1097/IGC.0b013e3182070f17
    Journal articles | 2011
    Vaughan S; Coward J; Bast R; Berchuck A; Berek JS; Brenton JD; Coukos G; Crum CC; Drapkin R; Etemadmoghadam D; Friedlander M; Gabra H; Kaye S; Lord CJ; Lengyel E; Levine DA; McNeish IA; Menon U; Mills G; Nephew KP; Oza AM; Sood A; Stronach EA; Walczak H; Bowtell D; Balkwill FR, 2011, 'Rethinking ovarian cancer: recommendations for improving outcomes.', Nature Reviews Cancer, vol. 11, pp. 719 - 725, http://dx.doi.org/10.1038/nrc3144
    Journal articles | 2009
    Mouridsen H; Giobbie-Hurder A; Goldhirsch A; Thuerlimann B; Paridaens R; Smith I; Mauriac L; Forbes JF; Price KN; Regan MM; Gelber RD; Coates AS, 2009, 'Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer', NEW ENGLAND JOURNAL OF MEDICINE, vol. 361, pp. 766 - 776, http://dx.doi.org/10.1056/nejmoa0810818
    Journal articles | 2009
    Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC, 2009, 'Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, vol. 27, pp. 1243 - 1249, http://dx.doi.org/10.1200/JCO.2008.19.3425
    Journal articles | 2009
    Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2009, 'Oxaliplatin-induced Lhermitte’s phenomenon as a manifestation of severe generalized nerve dysfunction', Oncology, vol. 77, pp. 342 - 348, http://dx.doi.org/10.1159/000265940
    Journal articles | 2009
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2009, 'Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy', Brain, vol. 132, pp. 2712 - 2723, http://dx.doi.org/10.1093/brain/awp219
    Journal articles | 2008
    Park SB; Krishnan AV; Lin CS; Goldstein D; Friedlander ML; Kiernan MC, 2008, 'Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies', Current Medicinal Chemistry: Cardiovascular and Hematological Agents, vol. 15, pp. 3081 - 3094, http://dx.doi.org/10.2174/092986708786848569
    Journal articles | 2006
    Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2006, 'Oxaliplatin and axonal Na+ channel function in vivo', Clinical Cancer Research, vol. 12, pp. 4481 - 4484, http://dx.doi.org/10.1158/1078-0432.CCR-06-0694
    Journal articles | 2005
    Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2005, 'Oxaliplatin-induced neurotoxicity and the development of neuropathy', Muscle and Nerve, vol. 32, pp. 51 - 60, http://dx.doi.org/10.1002/mus.20340
    Journal articles | 2000
    Bonevski B; Sanson-Fisher R; Girgis A; Burton L; Cook P; Boyes AW; Ackland S; Baker RW; Berry M; Biggs J, 2000, 'Evaluation of an instrument to assess the needs of patients with cancer', Cancer, vol. 88, pp. 217 - 225, http://dx.doi.org/10.1002/(SICI)1097-0142(20000101)88:1<217::AID-CNCR29>3.0.CO;2-Y
    Journal articles | 1998
    Kefford R; Tucker K; Friedlander M; Kirk J, 1998, 'Cancer in the family. Part 2.', Australian family physician, vol. 27, pp. 40 - 44
    Journal articles | 1998
    Links MJ; Ribeiro JC; Jackson P; Friedlander ML; Russell PJ, 1998, 'Regulation and deregulation of G2 checkpoint proteins with cisplatin', Anticancer Research, vol. 18, pp. 4057 - 4066
  • Conference Abstracts | 2021
    Friedlander M; Benson C; O'Connell RL; Reed N; Clamp A; Lord R; Millan D; Nottley S; Amant F; Steer C; Anand A; Mileshkin L; Beale P; Banerjee S; Bradshaw N; Kelly C; Carty K; Divers L; Alexander L; Edmondson R, 2021, 'Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)', in Gynecologic Oncology, United States, Vol. 161, pp. 160 - 165, United States, http://dx.doi.org/10.1016/j.ygyno.2021.02.016
    Conference Papers | 2017
    Desai J; Gan H; Barrow C; Jameson MB; Solomon B; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Gibbs D; Parente P; Yang J; Wang L; Chen Y; Luo L, 2017, 'Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', in Cancer Research, American Association for Cancer Research (AACR), pp. CT002 - CT002, presented at Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC, http://dx.doi.org/10.1158/1538-7445.am2017-ct002